IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#754
Positioning
Market Dominance
Manufacturing
Medical Equipment
$12.7B
Bryan C. Hanson
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Headcount
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = SOLV ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$SOLV Solventum Corp | 59 | 78 | 96 | 41 | 7.8x | 7.2x | 32.4% | 11.6% | 54.6% | 27.8% | 19.3% | 0.7% | 0.0% | 103.0x | $12.7B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Solventum Corp (SOLV) receives a "Hold" rating with a composite score of 59.4/100. It ranks #754 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Bryan C. Hanson
Chief Executive Officer
Labor Force
22,000
78
31
80
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for SOLV
22.0K
HQ Base
ST. PAUL, Minnesota
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for SOLV.
View All RatingsConservative accounting — High cash conversion efficiency
Material decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROIC 40.9% vs WACC 7.3% (spread +33.6%)
GM 55% vs sector 43%, OM 28% vs sector 1%
Capital turnover 0.60x, R&D intensity 8.9%
Rev growth 1%, 2yr history
Interest coverage 20.6x, Net debt/EBITDA 2.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns Solventum Corp a Hold rating, with a composite score of 59.4/100 and 3 out of 5 stars. Ranked #754 of 7,333 stocks, SOLV presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
SOLV earns a quality score of 78/100, indicating above-average business quality. The company reports a return on equity of 32.4% (sector avg: -2.5%), gross margins of 54.6% (sector avg: 42.5%), net margins of 19.3% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
From a valuation perspective, SOLV scores an exceptional 96/100, indicating the stock trades at a deep discount relative to its fundamentals. Key valuation metrics include a P/E ratio of 7.83x, an EV/EBITDA of 7.22x, a P/B ratio of 2.54x. A value score this high suggests the market may be significantly underpricing the company's earnings power, assets, or cash flow generation.
Solventum Corp's investment score of 31/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 0.7% vs. a sector average of 5.9% and a return on assets of 11.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
SOLV is currently showing below-average momentum at 41/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 0.7% year-over-year, while a beta of 0.92 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
SOLV shows good financial stability with a score of 80/100. Key stability metrics include a beta of 0.92 and a debt-to-equity ratio of 103.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 47/100 for SOLV suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 103.00x). With a $12.7B market cap (large-cap), Solventum Corp may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Solventum Corp is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #754 of 7,333 overall (90th percentile). Key comparisons include ROE of 32.4% exceeding the -2.5% sector median and operating margins of 27.8% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SOLV currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (96) vs Investment (31) — closing this gap could shift the rating.
EV/EBITDA 37% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 1406% BELOW SECTOR MEDIAN
Gross Margin 28% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Solventum Corp (SOLV) as a Hold with a composite score of 59.4/100 at a current price of $73.44. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in value (96th percentile) and stability (80th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (31th percentile) and momentum (41th percentile) tempers our overall conviction. We assign a Narrow Moat rating (62/100), Medium uncertainty, and Standard capital allocation.
Key items to watch: balance sheet deleveraging progress. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Solventum Corp holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 59.4/100 places it at rank #754 in our full 7,333-stock universe. With a $12.7B market capitalization, Solventum Corp operates at meaningful scale within the Manufacturing sector, providing competitive advantages in distribution, procurement, and customer reach.
Revenue is growing at 1%, though momentum at the 41th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 55% (+12.1pp vs sector) narrow to operating margins of 28% (+26.5pp vs sector) and net margins of 19.3%, yielding a gross-to-net conversion rate of 35%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $73.44, Solventum Corp appears undervalued relative to its fundamentals. Our value factor score of 96/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at a P/E of 7.8x (a 65% discount to the sector median of 22.3x), EV/EBITDA of 7.2x (discounted to peers), P/B of 2.5x, P/S of 1.5x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Gross margins of 55% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 32.4% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
A value factor score of 96/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
Return on assets of 11.6% indicates efficient deployment of the full asset base, not just equity capital.
Elevated leverage (103% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
We assign a Medium uncertainty rating to Solventum Corp. The stock presents a balanced risk profile: significant leverage (103% debt-to-equity). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: significant leverage (103% debt-to-equity). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 80th percentile and quality factor at the 78th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 55% provide a buffer against cost pressures; above-average stability (80th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Solventum Corp's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 32.4%, and the balance sheet is managed within acceptable parameters (D/E: 103%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; Solventum Corp falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, Solventum Corp receives a Hold rating with a composite score of 59.4/100 (rank #754 of 7,333). Our quantitative framework assigns a Narrow Moat (62/100, trend: stable), Medium uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 65/100.
Our analysis supports a neutral stance on Solventum Corp. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign Solventum Corp a Narrow Moat rating with a composite moat score of 62/100. The ROIC-WACC spread of +33.6% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that Solventum Corp can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 17.6/20.
The strongest moat sources are margin superiority (17.6/20) and economic value creation (17.5/20). GM 55% vs sector 43%, OM 28% vs sector 1%. ROIC 40.9% vs WACC 7.3% (spread +33.6%). These pillars form the core of Solventum Corp's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (3.4/20) and growth durability (8.5/20). Capital turnover 0.60x, R&D intensity 8.9%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Solventum Corp's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 55% providing a solid profitability foundation, operating margins of 28% reflecting effective cost management, returns on equity of 32.4% driving shareholder value creation. The margin cascade from 55% gross to 28% operating to 19.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 78th percentile.
The margin profile shows gross margins of 55%, operating margins of 28%, net margins of 19.3%. Return metrics include ROE of 32.4% and ROA of 11.6%. Relative to the Manufacturing sector, gross margins are 12.1 percentage points above the sector median of 43%, and ROE of 32.4% compares to a sector median of -2.5%.
The balance sheet reflects above-average leverage with D/E of 103%, revenue growth of 1%. The sector median D/E is 0%, putting Solventum Corp at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.

About Solventum Corp Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethos

Thermo Fisher Scientific has agreed to acquire Solventum's Purification & Filtration business for $4.1 billion, a strategic move to expand its bioproduction capabilities. The acquired business generated around $1 billion in revenue in 2024 and is expected to generate synergies and earnings accretion for Thermo Fisher.

Solventum reported strong Q3 2025 financial performance, with solid growth in MedSurg, Dental Solutions, and Health Information Systems segments. The company is advancing toward long-range revenue and earnings objectives faster than anticipated, with a focus on strategic acquisitions and operational efficiency.

3M has seen significant operational improvements under new CEO Bill Brown, with a focus on innovation, operational efficiency, and restructuring. The company has increased new product introductions by 70% and improved equipment effectiveness, positioning itself for potential future growth.

3M, a diversified conglomerate, has faced major challenges in recent years, including sluggish sales, safety-related recalls, and billions in legal settlements. However, the company's business has gradually stabilized, and its new CEO is taking steps to improve its performance, such as accelerating R&D and new product launches. While 3M's stock is reasonably valued, its turnaround efforts could take time to bear fruit, and there may be better investment options available.
Above 50MA
37.18%
Net New Highs
+51081